UPCC 16917 Genomic, Epigenetic, Proteomic, Metabolomic and Immunologic Characterization as well as Patient-Derived Model Development for Metastatic Neuroendocrine Tumors Prior to and Following Locoregional Therapy

Enrolling By Invitation
99 years or below
All
40 participants needed
1 Location

Brief description of study

mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells surviving TACE or TARE.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 22 Apr 2026. Study ID: 16-0204
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator